WPD Pharmaceuticals Inc. announced that first patient enrolled in the Phase 1B/2 clinical trial of Annamycin in the treatment of soft tissue sarcoma (STS) lung metastases, has received the first dose of Annamycin. The start of clinical trial is a consequence of the project granted by Agencja Bada Medycznych (The Medical Research Agency), that was communicated by WPD in a news release dated February 9, 2021. Agencja Bada Medycznych (The Medical Research Agency) is a Polish state agency responsible for development of scientific research in the field of medical and health sciences, awarded a grant equivalent to USD 1.5 million to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.045 CAD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 3.74M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- WBIO Stock
- News WPD Pharmaceuticals Inc.
- WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin